← Leaderboards
Ines Macias-Perez
Cumberland Pharmaceuticals, Inc.
$1,166,854
Attributed
$1,166,854
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2019–20$2M$1.5M$1M$500K$0
'19
'20
Funding mix
By agency
FDA$1,166,854 · 1
By mechanism
R01$1,166,854 · 1
Top collaborators
No co-investigators on record.
Grant awards (2)
A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018)$97,112
R01 · FY2020 · FD · contact PI
A Ph2 Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Musculary Dystrophy IND136895 (10/10/2018)$1,069,742
R01 · FY2019 · FD · contact PI